Prenatal Care Practice Questions

Q: Which of the following is not a part of the quadruple test for antenatal detection of Down syndrome?

Inhibin B. ***Inhibin B*** - The **quadruple test** uses **Inhibin A**, not Inhibin B, along with AFP, β-hCG, and unconjugated estriol to screen for Down syndrome. - **Inhibin B** is primarily associated with assessing ovarian reserve in non-pregnant women or testicular function in men. *Beta HCG* - **Elevated levels of beta-hCG** are characteristically seen in pregnancies affected by **Down syndrome**, making it a key component of the quadruple test. - This hormone is produced by the placenta and its measurement helps in risk assessment for chromosomal abnormalities. *AFP* - **Alpha-fetoprotein (AFP)** levels are typically **lower** in pregnancies with **Down syndrome**, contrasting with elevated levels in neural tube defects. - It is a fetal-specific protein and its measurement is crucial for the quadruple test's diagnostic accuracy. *Estriol* - **Unconjugated estriol (uE3)** levels are usually **decreased** in pregnancies affected by **Down syndrome**. - This steroid hormone is produced by the placenta and fetal adrenal glands, and its reduced levels are a significant marker in the quadruple test.

Q: 18 weeks pregnant female presents with no high risk of NTD and low risk of trisomy 21 on quad test. What is the most appropriate next step in management?

Perform a detailed fetal ultrasound.. ***Perform a detailed fetal ultrasound.*** - A **detailed fetal ultrasound** (often referred to as an **anatomy scan**) at around 18-22 weeks is a standard component of prenatal care for all pregnant women, regardless of screening test results. - This ultrasound evaluates fetal anatomy for structural anomalies, assesses fetal growth, and confirms gestational age, providing crucial information even with low-risk screening. *Repeat non-invasive screening test.* - Repeating a non-invasive screening test (like another quad screen or NIPT) is generally **not indicated** when initial results show a low risk and there are no other clinical concerns. - Such tests are primarily for screening purposes, and a second low-risk result would offer little additional actionable information, as their positive predictive value is low. *Perform invasive diagnostic testing.* - **Invasive diagnostic testing**, such as **amniocentesis** or **chorionic villus sampling (CVS)**, carries a risk of miscarriage and is reserved for situations with a high risk of chromosomal abnormalities or genetic conditions. - Given the low-risk quad screen results for trisomy 21 and no high risk for NTDs, invasive testing is **not warranted** at this stage. *Perform amniotic fluid analysis.* - **Amniotic fluid analysis** is part of an amniocentesis, an **invasive diagnostic procedure** designed to detect chromosomal abnormalities or genetic disorders. - This procedure is typically reserved for cases where screening tests indicate a high risk or there is a clinical suspicion of a genetic condition; it's **not a routine step** after a low-risk quad screen.

Q: A pregnant woman is diagnosed with iron deficiency anemia during her second trimester. Which of the following interventions is most appropriate to prevent adverse outcomes?

Oral iron supplementation and dietary counseling. ***Oral iron supplementation and dietary counseling*** - **Oral iron supplementation** is the **first-line treatment** for iron deficiency anemia in pregnancy, as it is effective and generally well-tolerated. - **Dietary counseling** helps improve iron intake from food sources and enhance absorption, complementing supplementation. *Only dietary counseling* - While **dietary counseling** is important, it is usually insufficient to correct established **iron deficiency anemia** during pregnancy due to increased iron demands. - Relying solely on diet can lead to prolonged anemia and **adverse maternal and fetal outcomes**. *Blood transfusion immediately* - **Blood transfusion** is reserved for cases of **severe, symptomatic anemia** or **hemodynamic instability**, which is not indicated here. - This intervention carries risks of **transfusion reactions** and is not the standard approach for moderate iron deficiency in pregnancy. *Intravenous iron supplementation* - **Intravenous iron** is considered for women who cannot tolerate or absorb oral iron, have severe anemia in late pregnancy, or in cases of non-compliance. - It is a more invasive option with potential side effects and is not the initial treatment of choice for a woman in her second trimester without severe symptoms.

Q: A 28-year-old woman at 10 weeks of gestation presents with severe vomiting, weight loss, and ketonuria. What is the most likely diagnosis?

Hyperemesis gravidarum. ***Hyperemesis gravidarum*** - Characterized by **severe nausea and vomiting** during pregnancy, typically in the **first trimester**, leading to **weight loss >5% of pre-pregnancy weight** and **ketonuria**. - It is distinct from typical morning sickness due to its severity and metabolic disturbances (dehydration, electrolyte imbalance, ketosis). - Most cases resolve by 20 weeks of gestation. *Gastroenteritis* - While it causes vomiting and may lead to ketonuria, it is typically an **acute, self-limiting viral or bacterial infection** lasting days, not weeks. - It would not typically present as a chronic condition causing significant weight loss over an extended period in pregnancy. - Usually accompanied by **diarrhea**, which is not mentioned in this case. *Preeclampsia* - This condition is characterized by **new-onset hypertension and proteinuria** after 20 weeks of gestation. - At **10 weeks gestation**, it is too early for preeclampsia to develop. - Vomiting can occur in severe cases, but it's not the primary symptom, and weight loss and ketonuria are not typical diagnostic features. *Gestational diabetes* - This involves **glucose intolerance** that develops or is first recognized during pregnancy, typically diagnosed at **24-28 weeks**. - Symptoms usually include **polyuria, polydipsia, and fatigue**, not severe vomiting, weight loss, or ketonuria. - Ketonuria in diabetes suggests ketoacidosis, which would present with hyperglycemia, not the clinical picture described.

Q: A 29-year-old woman with a history of preeclampsia in a previous pregnancy presents at 12 weeks of gestation. What is the recommended prophylactic treatment?

Aspirin. ***Aspirin*** - **Low-dose aspirin** is recommended for women with a history of preeclampsia, especially when started early in pregnancy (before 16 weeks of gestation). - It helps reduce the risk of recurrent preeclampsia by improving **placental perfusion** and inhibiting platelet aggregation. *Calcium supplements* - While recommended for women with **low dietary calcium intake**, calcium supplementation alone does not have the same strong evidence for prophylactic preeclampsia prevention as aspirin. - It's often used as an adjunct in high-risk pregnancies, but not typically as the primary prophylactic agent in this specific scenario. *Methyldopa* - **Methyldopa** is an **antihypertensive medication** used to treat existing hypertension in pregnancy. - It does not serve as a primary prophylactic agent to prevent the development of preeclampsia in a woman with a history of the condition. *Labetalol* - **Labetalol** is another **antihypertensive medication** commonly used to manage acute or chronic hypertension during pregnancy. - Similar to methyldopa, it is a treatment for established hypertension rather than a prophylactic measure against preeclampsia recurrence.

Q: In the context of prenatal care, what is the significance of the double marker test?

It assesses the risk of Down syndrome.. ***It assesses the risk of Down syndrome.*** - The **double marker test** measures levels of **free beta-human chorionic gonadotropin (hCG)** and **pregnancy-associated plasma protein-A (PAPP-A)** in maternal blood. - Abnormal levels of these markers, particularly a **high hCG** and **low PAPP-A**, are indicative of an increased risk of **Down syndrome (Trisomy 21)**. *It detects neural tube defects.* - **Neural tube defects** are primarily screened for using **alpha-fetoprotein (AFP)** levels, often part of the quadruple screen or maternal serum screening. - The double marker test components (hCG and PAPP-A) are not reliable markers for neural tube defects. *It evaluates fetal lung maturity.* - **Fetal lung maturity** is typically assessed later in pregnancy, often through analysis of **amniotic fluid** for ratios like **lecithin-sphingomyelin (L/S ratio)** or presence of **phosphatidylglycerol**. - The double marker test is performed in the first trimester and does not provide information about fetal lung development. *It screens for gestational diabetes.* - **Gestational diabetes** screening is performed later in pregnancy, usually between **24 and 28 weeks**, using a **glucose challenge test** followed by an oral glucose tolerance test if necessary. - The double marker test biomarkers are unrelated to glucose metabolism or the screening for gestational diabetes.

Q: During a routine prenatal visit, a 25-year-old woman at 18 weeks of gestation is found to have a low-lying placenta. What is the most appropriate management?

Schedule for a repeat ultrasound at 28 weeks. ***Schedule for a repeat ultrasound at 28 weeks*** - A **low-lying placenta** at 18 weeks is common, and in most cases, the placenta will "migrate" away from the cervix as the uterus grows. - A repeat ultrasound at **28 weeks (or later)** is necessary to assess whether the placenta has moved to a safe position for vaginal delivery or if it remains a **placenta previa**. *Immediate cesarean delivery due to complications* - **Cesarean delivery** is not indicated at 18 weeks based solely on a low-lying placenta, as it is a common finding that usually resolves. - Complications warranting immediate delivery, such as **severe bleeding** or **fetal distress**, are not mentioned here. *Bed rest until further evaluation* - **Bed rest** is generally not recommended for an uncomplicated low-lying placenta at this gestation, as it lacks evidence for efficacy and carries risks. - It might be considered in cases of **vaginal bleeding** with placenta previa, but not as a routine measure for this finding. *Initiate corticosteroids for fetal lung maturity* - **Corticosteroids** are given to accelerate **fetal lung maturity** in cases of anticipated preterm birth, typically before 34-37 weeks. - There is no indication of impending **preterm delivery** or other complications requiring corticosteroids at 18 weeks.

Q: A pregnant woman at 14 weeks of gestation shows increased nuchal thickness on ultrasound. Which test is NOT included in the second trimester quadruple test for Down's syndrome?

PAPP-A. ***PAPP-A*** - **Pregnancy-associated plasma protein-A (PAPP-A)** is a marker included in the **first-trimester screening** for Down syndrome, primarily performed between weeks 10 and 14 of gestation. - The question specifies the **second-trimester quadruple screen**, therefore, PAPP-A is **NOT part of this test**. - This is the **correct answer** as it is the only marker listed that is NOT included in the second-trimester quadruple test. *AFP* - **Alpha-fetoprotein (AFP)** is one of the four markers measured in the **quadruple screen** during the second trimester. - Low levels of AFP, combined with other markers, can indicate an increased risk of **Down syndrome**. *hCG* - **Human chorionic gonadotropin (hCG)** is another marker included in the **second-trimester quadruple screen**. - **Elevated levels of hCG** are associated with an increased risk for Down syndrome. *Inhibin A* - **Inhibin A** is the fourth marker in the **quadruple screen**, alongside AFP, hCG, and **unconjugated estriol (uE3)**. - **Elevated levels of Inhibin A** in the second trimester are suggestive of an increased risk of Down syndrome. **Note:** The complete second-trimester quadruple screen includes: AFP, hCG, unconjugated estriol (uE3), and Inhibin A. PAPP-A is used only in first-trimester screening.

Q: What is the recommended daily dose of folic acid supplementation for pregnant women according to current Indian guidelines?

500 micrograms daily. ***500 micrograms daily*** - This is the **recommended dose** according to **ICMR-NIN (2020)** and **FOGSI guidelines** for pregnant women in India. - **WHO recommends 400-800 mcg daily**, and 500 mcg falls within this evidence-based range. - This dose effectively **prevents neural tube defects** (NTDs) like spina bifida and anencephaly when taken periconceptionally and during early pregnancy. - Should be started **at least one month before conception** and continued through the first trimester. *400 micrograms daily* - This was the older recommended dose and is still acceptable as per some international guidelines (USPSTF, older ACOG recommendations). - However, **current Indian guidelines specifically recommend 500 mcg** as the standard dose for the Indian population. - Still within the effective range but not the specific Indian recommendation. *200 micrograms daily* - This dose is **insufficient** for effective prevention of neural tube defects during pregnancy. - Does not meet the **increased folate demands** during pregnancy for DNA synthesis and fetal development. *800 micrograms daily* - This is at the **upper end of the WHO recommended range** (400-800 mcg). - While not harmful and still within safe limits, it is **higher than the standard Indian recommendation** of 500 mcg. - High-dose folic acid (4-5 mg daily) is reserved for **high-risk women** with previous NTD-affected pregnancy, diabetes, or on anticonvulsants.

Q: A 35-year-old woman at 12 weeks of gestation presents with severe nausea and vomiting, weight loss, and dehydration. What is the diagnosis?

Hyperemesis gravidarum. ***Hyperemesis gravidarum*** - This condition is characterized by **severe, persistent nausea and vomiting** during pregnancy, often leading to **weight loss** and **dehydration**. - It typically begins in the first trimester, peaking around 9-13 weeks, consistent with the patient's 12 weeks gestation. *Preeclampsia* - Preeclampsia usually manifests after **20 weeks of gestation** with symptoms like **hypertension**, **proteinuria**, and sometimes edema, which are not described here. - While preeclampsia can cause vomiting in severe cases, the primary symptoms are blood pressure and kidney-related. *Acute fatty liver of pregnancy* - This is a rare and severe liver disorder that typically occurs in the **third trimester** of pregnancy. - It presents with symptoms like nausea, vomiting, abdominal pain, and jaundice, but the timing is inconsistent with this patient's presentation. *Gastroenteritis* - While gastroenteritis causes nausea, vomiting, and dehydration, it is typically an **acute, self-limiting infection** and wouldn't be specifically tied to the pregnancy itself without further evidence of infection. - The severity and chronicity suggested by "severe nausea and vomiting" and "weight loss" are more indicative of hyperemesis gravidarum in a pregnant woman.

Question 1

Which of the following is not a part of the quadruple test for antenatal detection of Down syndrome?

Accepted Answer

Inhibin B

Answer

Beta HCG

Answer

AFP

Answer

Estriol

Question 2

18 weeks pregnant female presents with no high risk of NTD and low risk of trisomy 21 on quad test. What is the most appropriate next step in management?

Accepted Answer

Perform a detailed fetal ultrasound.

Answer

Repeat non-invasive screening test.

Answer

Perform invasive diagnostic testing.

Answer

Perform amniotic fluid analysis.

Question 3

A pregnant woman is diagnosed with iron deficiency anemia during her second trimester. Which of the following interventions is most appropriate to prevent adverse outcomes?

Accepted Answer

Oral iron supplementation and dietary counseling

Answer

Only dietary counseling

Answer

Blood transfusion immediately

Answer

Intravenous iron supplementation

Question 4

A 28-year-old woman at 10 weeks of gestation presents with severe vomiting, weight loss, and ketonuria. What is the most likely diagnosis?

Accepted Answer

Hyperemesis gravidarum

Answer

Gastroenteritis

Answer

Preeclampsia

Answer

Gestational diabetes

Question 5

A 29-year-old woman with a history of preeclampsia in a previous pregnancy presents at 12 weeks of gestation. What is the recommended prophylactic treatment?

Accepted Answer

Aspirin

Answer

Calcium supplements

Answer

Methyldopa

Answer

Labetalol

Question 6

In the context of prenatal care, what is the significance of the double marker test?

Accepted Answer

It assesses the risk of Down syndrome.

Answer

It detects neural tube defects.

Answer

It evaluates fetal lung maturity.

Answer

It screens for gestational diabetes.

Question 7

During a routine prenatal visit, a 25-year-old woman at 18 weeks of gestation is found to have a low-lying placenta. What is the most appropriate management?

Accepted Answer

Schedule for a repeat ultrasound at 28 weeks

Answer

Immediate cesarean delivery due to complications

Answer

Initiate corticosteroids for fetal lung maturity

Answer

Bed rest until further evaluation

Question 8

A pregnant woman at 14 weeks of gestation shows increased nuchal thickness on ultrasound. Which test is NOT included in the second trimester quadruple test for Down's syndrome?

Accepted Answer

PAPP-A

Answer

hCG

Answer

Inhibin A

Answer

AFP

Question 9

What is the recommended daily dose of folic acid supplementation for pregnant women according to current Indian guidelines?

Accepted Answer

500 micrograms daily

Answer

400 micrograms daily

Answer

200 micrograms daily

Answer

800 micrograms daily

Question 10

A 35-year-old woman at 12 weeks of gestation presents with severe nausea and vomiting, weight loss, and dehydration. What is the diagnosis?

Accepted Answer

Hyperemesis gravidarum

Answer

Acute fatty liver of pregnancy

Answer

Preeclampsia

Answer

Gastroenteritis

Prenatal Care — MCQs

Prenatal Care — MCQs

On this page

Practice by Chapter

Want unlimited practice?